obsolete_cystic fibrosis: ['A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather. -- 2003', 'A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather.']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
59 |
4. Check minimum number of eventsNone |
59 |
5. Include endpointsNone |
59 |
6. Filter based on genotype QC (FinnGen only) |
58 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cystic fibrosis, other manifestations/unspecified
based on the number of shared cases.
Similar with more cases:
- Cystic fibrosis
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 334 | 163 | 167 |
| Only index persons | 240 | 118 | 122 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.00 | 0.00 |
| Only index persons | 0.00 | 0.00 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 17.26 | 21.54 | 12.15 |
| Only index persons | 16.03 | 20.33 | 11.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 58 | 33 | 25 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 10.52 | 15.19 | 4.37 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 59
- Matched controls
- 590
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E84.9
ICD-10 Finland
Cystic fibrosis, unspecified
+∞
56.7
45
*
E84.0
ICD-10 Finland
Cystic fibrosis with pulmonary manifestations
+∞
43.1
36
*
304
Kela drug reimbursment
Dornase alfa
+∞
37.5
32
*
R05CB13
ATC
dornase alfa (desoxyribonuclease); inhalant
+∞
37.5
32
*
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
225.1
33.8
32
*
J01GB01
ATC
tobramycin; inhalant, parenteral
+∞
33.6
29
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
315.6
33.5
31
*
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
516.5
30.8
28
*
E84.1
ICD-10 Finland
Cystic fibrosis with intestinal manifestations
+∞
28.4
25
*
E84.8
ICD-10 Finland
Cystic fibrosis with other manifestations
+∞
25.9
23
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
16.9
25.3
27
28
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
41.7
24.8
31
15
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
341.7
23.4
22
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
49.9
22.1
26
9
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
12.3
21.8
33
55
TGC00
NOMESCO Finland
Bronchial lavation
295.1
21.0
20
*
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
31.8
20.3
27
15
J18.9
ICD-10 Finland
Pneumonia, unspecified
11.0
19.9
35
69
J01XB01
ATC
colistin; inhalant, parenteral
+∞
19.9
18
*
2770A
ICD-9 Finland
Other and unspecified disorders of metabolism, Cystic fibrosis
+∞
18.7
17
*
GD1AD
NOMESCO Finland
Thorax CT examination
48.7
18.7
22
7
R4190
NOMESCO Finland
Nutritional therapy
36.5
18.2
23
10
UGC12
NOMESCO Finland
Flexible bronchoscopy
27.8
17.5
24
14
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
34.0
17.2
22
10
L04AA06
ATC
mycophenolic acid; systemic
84.3
16.9
18
*
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
42.0
16.5
20
7
J01MA12
ATC
levofloxacin; systemic
9.2
16.4
29
56
J01MA02
ATC
ciprofloxacin; systemic
9.1
16.4
39
104
J32.4
ICD-10 Finland
Chronic pansinusitis
214.6
16.4
16
*
XG410
NOMESCO Finland
Flow-volume spirometry
36.7
16.0
20
8
R4110
NOMESCO Finland
Physiotherapy
8.5
15.8
35
86
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
8.6
15.7
31
67
J33.0
ICD-10 Finland
Polyp of nasal cavity
107.3
15.4
16
*
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
+∞
15.2
14
*
E84
ICD-10 Finland
Cystic fibrosis
+∞
15.2
14
*
Z94.2
ICD-10 Finland
Lung transplant status
196.8
15.2
15
*
L04AD02
ATC
tacrolimus; systemic
196.8
15.2
15
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
9.3
15.2
44
141
TDM10
NOMESCO Finland
Puncture of maxillary antrum
29.3
15.1
20
10
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
19.0
14.8
23
19
UDH02
NOMESCO Finland
Rhinopharyngoscopy
16.7
14.5
24
23
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
22.4
14.5
21
14
127
Kela drug reimbursment
Transplant complication
46.6
14.4
17
5
GDG10
NOMESCO Finland
Bilateral transplantation of lung
+∞
14.1
13
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
25.1
13.1
18
10
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
163.3
13.0
13
*
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
+∞
13.0
12
*
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
59.9
12.5
14
*
R03BA02
ATC
budesonide; inhalant
7.2
12.4
26
58
ZX120
NOMESCO Finland
Intravenous
18.0
12.2
19
15
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.7
12.2
34
100
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
19.3
11.9
18
13
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
17.9
11.6
18
14
WX404
NOMESCO Finland
Intravenous generell anesthesy
6.6
11.5
27
67
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
54.3
11.4
13
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
19.3
11.3
17
12
602
Kela drug reimbursment
Children's severe malnutrition
35.8
11.3
14
5
215
Kela drug reimbursment
Diabetes, non-insulin-treated
6.8
10.9
23
51
R03BA05
ATC
fluticasone; inhalant
6.4
10.9
26
65
TPX10
NOMESCO Finland
Implantation of vascular injection port
40.8
10.8
13
*
R07AX32
ATC
ivacaftor, tezacaftor and elexacaftor; oral
+∞
10.7
10
*
3045, ,
Kela drug reimbursment
+∞
10.7
10
*
B05XA03
ATC
sodium chloride; parenteral
+∞
10.7
10
*
R07AX02
ATC
ivacaftor; oral
+∞
10.7
10
*
WX408
NOMESCO Finland
General anesthesy, balanced
6.1
10.7
28
76
J01MA14
ATC
moxifloxacin; systemic
16.5
10.7
17
14
Z3226
NOMESCO Finland
Physiotherapist
6.3
10.5
25
62
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.9
10.5
21
44
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
17.7
10.4
16
12
103
Kela drug reimbursment
Diabetes, insulin-treated
6.3
10.4
24
58
R04.2
ICD-10 Finland
Haemoptysis
66.3
10.0
11
*
A10AB05
ATC
insulin aspart; parenteral
12.4
9.9
18
20
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
5.8
9.8
25
66
DPA25
NOMESCO Finland
Trephine of frontal sinus through nose
118.2
9.7
10
*
27300
ICD-8 Finland
Other and unspecified congenital disorders of metabolism, Cystic fibrosis (mucoviscidosis)
+∞
9.6
9
*
XX4BW, ,
NOMESCO Finland
+∞
9.6
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
6.0
9.6
23
57
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
23.2
9.4
13
7
UDM02
NOMESCO Finland
Sinoscopy
44.2
9.4
11
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
29.5
9.3
12
5
J01CF05
ATC
flucloxacillin; systemic
11.4
9.1
17
20
R03AK06
ATC
salmeterol and fluticasone; inhalant
8.6
8.9
20
33
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
33.1
8.8
11
*
ZXA10
NOMESCO Finland
Bilateral
5.5
8.8
23
61
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
18.0
8.7
13
9
R01AD08
ATC
fluticasone; nasal
5.1
8.7
28
89
K90.3
ICD-10 Finland
Pancreatic steatorrhoea
104.4
8.7
9
*
DHB20
NOMESCO Finland
Polypectomy of internal nose
+∞
8.5
8
*
UJF32
NOMESCO Finland
Coloscopy
5.7
8.3
20
49
OAB50, ,
SPAT
18.4
8.1
12
8
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
52.2
8.0
9
*
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
52.2
8.0
9
*
A05AA02
ATC
ursodeoxycholic acid; oral
22.0
7.9
11
6
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
29.5
7.9
10
*
Z3229
NOMESCO Finland
Other healthcare associate professional
9.1
7.6
16
23
R05CB02
ATC
bromhexine; systemic
91.1
7.6
8
*
RS123, ,
NOMESCO Finland
91.1
7.6
8
*
DPA30
NOMESCO Finland
Sphenotomy
91.1
7.6
8
*
Z2446
NOMESCO Finland
Social worker
9.6
7.5
15
20
Z31.5
ICD-10 Finland
Genetic counselling
9.6
7.5
15
20
J33.8
ICD-10 Finland
Other polyp of sinus
+∞
7.4
7
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
23.6
7.4
10
5
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
4.4
7.4
33
132
ZXE10
NOMESCO Finland
More than one and less than three hours
4.4
7.3
31
119
A02BA03
ATC
famotidine; systemic
26.0
6.9
9
*
UDC00
NOMESCO Finland
Ear microscopy
10.1
6.8
13
16
H02AB06
ATC
prednisolone; systemic
4.1
6.7
34
147
WX872
NOMESCO Finland
Intensive care
11.2
6.7
12
13
J47
ICD-10 Finland
Bronchiectasis
77.9
6.6
7
*
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
77.9
6.6
7
*
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
30.3
6.4
8
*
Z94.0
ICD-10 Finland
Kidney transplant status
30.3
6.4
8
*
R03AC02
ATC
salbutamol; inhalant
4.8
6.4
46
251
J02AC04
ATC
posaconazole; systemic
+∞
6.4
6
*
V07AB
ATC
Solvents and diluting agents, incl. irrigating solutions
+∞
6.4
6
*
DM1BG
NOMESCO Finland
Paranasal sinuses and face area standard MRI examination with high intensity magnet
+∞
6.4
6
*
R03AC03
ATC
terbutaline; inhalant
6.7
6.3
16
31
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
7.1
6.2
15
27
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
9.7
6.2
12
15
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.6
6.2
14
23
SPAT1262
SPAT
Handing over of treatment supplies
6.5
6.1
16
32
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.9
6.0
16
42
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
4.7
6.0
17
47
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
10
62.94
27.35
5.4
1.8
3.42
3.38
g/l
—
31
10
29
8
68.87
26.14
6.2
3.1
156.69
145.75
%
—
29
8
30
39
14.62
24.10
7.4
1.7
0.20
0.23
g/l
1.49
30
34
24
7
55.98
20.93
7.0
2.0
—
—
—
0
0
33
63
10.62
19.22
5.3
2.0
—
—
—
0
0
28
45
10.94
18.71
4.1
1.7
—
—
—
0
0
28
45
10.94
18.71
4.5
1.7
—
—
—
0
0
22
7
48.73
18.69
5.2
1.1
—
—
—
0
0
23
10
36.48
18.22
4.5
1.5
—
—
—
0
0
23
10
36.48
18.22
5.2
1.5
—
—
—
0
0
32
63
9.91
17.99
4.6
2.2
12.14
13.06
umol/l
0.29
32
58
20
6
49.03
17.08
4.1
1.2
—
—
—
0
0
21
10
31.61
16.10
25.0
5.4
107.40
—
iu/ml
—
5
0
20
8
36.74
16.00
4.4
1.5
—
—
—
0
0
25
43
9.35
15.50
11.0
5.6
103.16
105.00
mmol/l
0.65
25
43
19
8
34.05
14.96
5.0
1.3
—
—
—
0
0
48
173
10.52
14.55
23.5
4.4
1.20
1.22
mmol/l
0.83
38
140
37
104
7.86
14.35
4.9
1.6
1.43
0.91
mg/l
0.32
25
69
13
0
+∞
14.11
4.5
0.0
—
—
—
0
0
17
7
33.24
13.38
5.0
1.3
—
—
—
0
0
26
56
7.51
12.92
5.1
2.2
2.50
2.50
g/l
0.01
26
51
17
8
29.04
12.91
4.4
1.3
—
—
—
0
0
40
139
6.83
11.89
10.1
2.2
27.10
28.20
u/l
0.20
40
126
13
6
27.15
9.85
2.8
1.5
—
—
—
0
0
33
112
5.42
9.62
3.5
1.9
2.81
2.67
mg/l
0.20
33
93
12
7
21.01
8.49
3.8
1.9
—
—
—
0
0
10
5
23.59
7.41
3.2
1.2
—
—
—
0
0
10
5
23.59
7.41
2.0
1.0
—
—
—
0
0
10
6
19.64
7.02
3.3
1.2
—
—
—
0
0
17
35
6.39
6.39
1.9
2.1
341.65
370.67
nmol/l
0.12
17
30
14
23
7.62
6.15
3.9
1.6
—
—
—
0
0
32
139
3.85
6.12
1.7
1.5
0.48
1.37
u/ml
—
5
21
9
6
17.33
6.12
1.3
1.5
95.00
128.33
%
—
9
6
8
5
18.16
5.58
1.1
1.4
73.63
117.60
%
—
8
5
32
147
3.57
5.48
12.4
12.2
1.09
1.22
inr
0.89
15
53
5
0
+∞
5.28
7.0
0.0
—
—
—
0
0
14
30
5.78
5.09
9.6
4.1
1.14
1.00
mmol/l
—
9
25
10
13
8.99
5.09
5.8
7.2
1.64
1.18
mg/l
—
10
13
8
8
11.32
4.67
1.1
1.3
—
—
—
0
0
32
159
3.21
4.64
9.2
3.2
—
—
—
0
0
20
76
3.47
4.47
6.3
2.7
1.73
1.34
e6/l
0.15
15
41
8
9
10.05
4.43
5.1
1.3
—
—
—
0
0
10
18
6.45
4.18
1.2
1.2
—
—
—
0
0
11
24
5.38
3.98
1.9
2.2
—
—
—
0
0
8
13
6.92
3.63
8.0
5.0
61.50
51.15
%
—
8
13
53
404
4.06
3.54
5.9
3.2
1.29
1.21
mmol/l
0.38
47
367
7
10
7.76
3.47
1.1
1.3
—
—
—
0
0
54
421
4.33
3.26
6.6
3.5
1.45
1.46
mmol/l
0.07
49
384
54
425
4.19
3.25
6.9
3.5
4.07
4.66
mmol/l
3.19
49
390
26
137
2.61
3.11
2.2
1.6
84.99
100.47
pmol/l
1.02
14
62
54
430
4.01
3.05
6.9
3.8
2.19
2.80
mmol/l
5.36
49
390
5
5
10.75
3.03
2.2
1.4
—
—
—
0
0
6
9
7.26
2.94
2.3
2.3
—
—
—
0
0
48
347
3.06
2.93
6.1
3.6
14.11
14.45
pmol/l
0.35
42
307
8
18
4.96
2.91
15.4
4.3
25.80
25.27
mmol/l
—
8
18
8
21
4.23
2.57
2.8
1.3
—
—
—
0
0
53
426
3.40
2.55
33.5
9.4
89.52
93.76
ml/min/173m2
0.42
47
325
52
419
3.03
2.45
7.7
4.1
1.96
1.86
mu/l
0.28
46
376
5
8
6.70
2.42
2.4
1.3
—
—
—
0
0
33
217
2.18
2.21
6.7
4.4
0.00
0.00
estimate
-0.00
12
46
24
139
2.22
2.20
2.9
3.2
47.45
51.11
ng/l
0.04
17
78
18
92
2.38
2.20
4.6
2.1
—
—
—
0
0
33
219
2.15
2.14
4.3
3.4
0.00
0.00
estimate
-0.00
11
48
33
222
2.10
2.04
4.3
3.3
0.00
0.00
estimate
-0.00
11
46
16
80
2.37
2.04
5.4
2.7
0.21
0.60
e6/l
1.07
11
44
5
11
4.85
1.98
1.6
1.1
—
—
—
0
0
5
11
4.85
1.98
4.2
1.9
0.57
0.67
ug/l
—
5
11
5
11
4.85
1.98
1.6
1.1
—
—
—
0
0
6
19
3.39
1.71
2.3
1.8
0.92
1.21
g/l
—
6
19
6
19
3.39
1.71
2.3
1.8
0.22
0.21
g/l
—
6
19
13
64
2.32
1.69
1.6
1.6
1052.63
1313.30
nmol/l
—
8
42
7
147
0.41
1.61
1.6
1.7
—
—
—
0
0
5
15
3.54
1.55
1.8
3.0
—
—
—
0
0
25
168
1.85
1.42
3.8
3.4
—
—
—
0
0
19
118
1.90
1.37
3.4
3.9
0.00
0.00
estimate
—
9
45
54
477
2.56
1.30
56.7
10.5
16.66
20.94
mg/l
0.87
49
346
10
51
2.16
1.19
3.9
3.9
272.20
219.67
u/l
—
10
46
8
40
2.15
1.17
3.9
3.6
—
—
—
0
0
49
424
1.92
1.04
6.2
3.4
6.12
5.65
mmol/l
1.32
44
380
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
0
31
0.00
0.99
0.0
1.7
—
—
—
0
0
0
32
0.00
0.98
0.0
1.6
—
—
—
0
0
28
212
1.61
0.97
4.9
2.3
—
—
—
0
0
0
27
0.00
0.79
0.0
1.7
—
—
—
0
0
5
27
1.93
0.70
2.0
1.1
—
—
—
0
0
7
47
1.55
0.50
1.0
1.0
—
—
—
0
0
0
15
0.00
0.42
0.0
1.8
—
—
—
0
0
0
16
0.00
0.42
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
42.65
—
0
17
10
124
0.77
0.24
1.5
3.0
—
—
—
0
0
5
42
1.21
0.22
1.2
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
7
80
0.86
0.07
1.7
2.2
—
—
—
0
0
40
407
0.95
0.01
4.2
3.6
—
—
—
0
0
10
94
1.08
0.01
1.6
1.3
—
—
—
0
0
11
114
0.96
0.00
1.5
2.7
—
—
—
0
0
5
52
0.96
0.00
19.8
4.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
14.20
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
326.50
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
15.59
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint E4_CYSTFIBRO_NAS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_CYSTFIBRO_NAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_CYSTFIBRO_NAS – Cystic fibrosis, other manifestations/unspecified
GWS hits: 9
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data